TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02087917

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HS-25
Description: Assigned study drug (HS-25 or placebo) is to be administered orally once daily in the morning with or without food. Treatment duration 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HS-25
Description: Assigned study drug (HS-25 or placebo) is to be administered orally once daily in the morning with or without food. Treatment duration 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Assigned study drug (HS-25 or placebo) is to be administered orally once daily in the morning with or without food. Treatment duration 4 weeks.
Study: NCT01456429

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic endosonography
Description: Endobronchial-ultrasound controlled transbronchial needle aspiration (EBUS-TBNA) in combination with a transoesophageal-ultrasound controlled needle aspiration of mediastinal lymph nodes
Study: NCT02012452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco treatment
Description: participants will be provided contingency management and cognitive behavioral therapy to help them quit tobacco prior to PTSD treatment

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Health Education
Description: Participants will be provided education on a variety of health topics and will set health goals around each topic
Study: NCT04104789

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Articaine Injection
Description: Local anesthetic
Study: NCT03726307

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCreg: 1.2 million cells/kg+SOC
Description: DCreg 1.2 (±02) million cells/kilogram body weight infused as a single dose.~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:~* mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and~* the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide.
Study: NCT04482127

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SubEpithelial connective graft
Description: Connective tissue graft harvested from hard palate, to be placed buccal to extraction sockets in the intervention group
Study: NCT00867035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorine dioxide and scraper
Description: 20ml of mouthwash used for 30sec as adjunct to tongue scraper twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate and scraper
Description: The intervention was accomplished by subject after instructions by investigator: twice a day the scraper was used for 4 strokes then 20ml 0.12% chlorhexidine gluconate rinse for 30sec, for one week.
Study: NCT03391882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-130277
Description: APL-130277: Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: subcutaneous apomorphine
Description: subcutaneous apomorphine Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A
Study: NCT02464748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TiM telehealth arm
Study: NCT03726307

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCreg:2.5 to 5.0 million cells/kg+SOC
Description: DCreg 2.5 to 5.0 million cells/kilogram body weight infused as a single dose.~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:~* mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and~* the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide.
Study: NCT02488252

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Routine medical care (active comparator)
Description: Angiotensin converting enzyme inhibitor or angiotensin receptor blocker at stable dose
Study: NCT06544382

Intervention type: OTHER
Intervention: The Long COVID Rehabilitation Intervention
Description: The intervention is a structured rehabilitation intervention with a duration of minimum 3 months comprising 4-12 individual sessions and 1-4 group-based courses delivered by physiotherapists and occupational therapists.
Study: NCT03263078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: For the maintenance of anesthesia, we used 2% propofol (Fresofol®, Fresenius Kabi, Germany) administered by the target controlled infusion (TCI) system (Orchestra® Base Primea; Fresenius Kabi, Germany) in Schnider mode with an effect concentration (Ce) of 2.5-3.5 µg ml-1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Anesthesia was maintained using 1-3% sevoflurane (ULTANE®, AbbVie Inc., USA) in the Sevoflurane group.
Study: NCT01828645

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate plus whey protein enriched drink
Description: The patients will drink 200 mL of the nutritional supplement (Jucy, Fresenius Kabi, Brazil) 2h before upper digestive endoscopy under sedation with propofol.
Study: NCT00814606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Description: Week 1: Fluvastatin 20mg daily Week 3: Fluvastatin 40mg daily Week 5: Fluvastatin 60mg daily Week 7: Fluvastatin 80 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa2a
Description: 180 mcg/ml SQ injection once a week for 48 weeks (starting at week 9)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 1000-1200 mg daily orally in two divided doses for 48 weeks (starting at week 9)
Study: NCT01619579

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVACEN Thermal Exchange System
Description: Non-invasive device forms vacuum around subject's hand, enabling efficient core body temperature adjustment using heating element inside device.
Study: NCT02170831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS low

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS medium 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS medium 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS high

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BIBR 1048 MS placebo
Study: NCT03710902

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ECG monitoring for 3 weeks
Description: A 3-week continuous ECG monitoring to detect occult AF.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-monitoring of BP and self-titration of antihypertensive medication
Description: One-week monthly self-monitoring of BP and self-titration of antihypertensive medication according to a pre-specified protocol, assisted with a mobile device application.
Study: NCT01790230

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LifeSeal™ Kit
Description: Application of LifeSeal™ Kit for staple line reinforcement during open GI surgeries in Low Anterior Resection
Study: NCT02896543

Intervention type: OTHER
Intervention: measurement
Description: Blood is obtained into ethylene diamine tetraacetic acid（EDTA） tubes from all subjects via antecubital vein puncture to measure the number of dendritic cells(DCs) and the concentration of sP-selectin. The number of dendritic cells(DCs) and the concentration of sP-selectin are measured in all patients with STEMI at 0 and 5-7 days after admission. The number of dendritic cells(DCs) and the only once in control group after admission.

Intervention type: OTHER
Intervention: measurement
Description: Blood is obtained into ethylene diamine tetraacetic acid（EDTA） tubes from all subjects via antecubital vein puncture to measure the number of dendritic cells(DCs) and the concentration of sP-selectin. The number of dendritic cells(DCs) and the concentration of sP-selectin are measured in all patients with STEMI at 0 and 5-7 days after admission. The number of dendritic cells(DCs) and the only once in control group after admission.
Study: NCT01723150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem
Study: NCT03988101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20mg
Description: Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin 20 mg once daily or equivalent.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin 20 mg once daily or equivalent.
Study: NCT06544382

Intervention type: OTHER
Intervention: Usual care
Description: A less structured rehabilitation programme comprising individual session with a few group options with patients with long COVID or mixed diagnoses.
Study: NCT00803933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB289
Description: Pafuramidine maleate (DB289), 100 mg BID orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentamidine
Description: Pentamidine isethionate (Aventis) for injection (200 mg/vial), 4 mg/kg QD IM
Study: NCT03870854

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEFA VT ablation technique
Description: Catheter ablation guided by PEFA technique
Study: NCT04361253

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-Titer COVID-19 Convalescent Plasma (HT-CCP)
Description: 250mL HT-CCP x2 doses given sequentially.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard Plasma (FFP)
Description: 250mL FFP or FP24 x2 doses given sequentially.
Study: NCT01235949

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK1024850A (SynflorixTM)
Description: Intramuscular injection, 4 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK1024850A (SynflorixTM)
Description: Intramuscular injection, 4 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK1024850A (SynflorixTM)
Description: Intramuscular injection, 4 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK1024850A (SynflorixTM)
Description: Intramuscular injection, 4 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK1024850A (SynflorixTM)
Description: Intramuscular injection, 4 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK1024850A (SynflorixTM)
Description: Intramuscular injection, 4 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK1024850A (SynflorixTM)
Description: Intramuscular injection, 4 doses
Study: NCT00931463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir
Description: 400 mg raltegravir tablet taken every 12 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2N(t)RTI
Description: 2N(t)RTIs as prescribed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir-boosted lopinavir
Description: 2 heat-stable tablets of ritonavir-boosted lopinavir taken every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted lopinavir
Description: 2 heat-stable tablets of ritonavir-boosted lopinavir taken every 12 hours
Study: NCT02326363

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Relapse Prevention (MBRP)
Description: Each session has a central theme/topic and consists of in-session experiential practice, discussions and homework assignments. Sessions begin with a check-in followed by a 20-30 minute meditation (i.e. body scan). The therapist reviews homework assignments, discusses challenges and participants are taught a variety of MM practices such as breath meditation, urge surfing, walking or movement meditation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Twelve-Step Facilitation Intervention (TSF)
Description: The primary goal is to promote abstinence by facilitating the patient's acceptance and surrender of addiction. Sessions begin with a check-in during which participants introduce themselves, report on meeting attendance and participation in related activities, any alcohol/drug use or craving to use. The remainder of the session focuses on discussion of the topic content followed by a take home summary and homework assignment.
Study: NCT01529476

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: levofloxacin 500 mg,QD,7\~10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemonoxacin
Description: Nemonoxacin 500mg,QD,7\~10 days
Study: NCT03859986

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ALX-101 Gel Vehicle
Description: ALX-101 Gel Vehicle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALX-101 Gel 5%
Description: ALX-101 Gel 5%
Study: NCT02460926

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling & Root Planing
Description: It consists in the non-surgical debridement of the sub gingival area affected by periodontal disease
Study: NCT04429919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP-325
Description: During the 10-day double-blind treatment period (Days 1 to 10), subjects will take 4 capsules of the IMP orally once daily in the morning before breakfast.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During the 10-day double-blind treatment period (Days 1 to 10), subjects will take 4 capsules of the IMP orally once daily in the morning before breakfast.
Study: NCT03403686

Intervention type: BIOLOGICAL
Intervention: blood draw
Description: Blood sample will be obtained and CD34+ cells will be isolated for functional testing.

Intervention type: BIOLOGICAL
Intervention: blood draw
Description: Blood sample will be obtained and CD34+ cells will be isolated for functional testing.
Study: NCT02629588

Intervention type: BEHAVIORAL
Intervention: Multimodal or Unimodal Sensory stimulation
Description: multimodal sensory stimulation, unimodal sensory stimulation, auditory stimulation, complex stimulation, median nerve stimulation.
Study: NCT04830917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immobilization type for mallet injury
Description: Method to hold the DIP joint in full extension to allow healing of terminal tendon injury/mallet injury

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immobilization type for mallet injury
Description: Method to hold the DIP joint in full extension to allow healing of terminal tendon injury/mallet injury
Study: NCT03403686

Intervention type: BIOLOGICAL
Intervention: blood draw
Description: Blood sample will be obtained and CD34+ cells will be isolated for functional testing.

Intervention type: BIOLOGICAL
Intervention: blood draw
Description: Blood sample will be obtained and CD34+ cells will be isolated for functional testing.

Intervention type: BIOLOGICAL
Intervention: blood draw
Description: Blood sample will be obtained and CD34+ cells will be isolated for functional testing.

Intervention type: BIOLOGICAL
Intervention: blood draw
Description: Blood sample will be obtained and CD34+ cells will be isolated for functional testing.
Study: NCT03874559

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Draw
Description: Serum samples will be obtained from each patient enrolled
Study: NCT05478876

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: carbon ion radiation therapy CIRT
Description: CIRT: The low-dose CTV (clinical target volume) will receive a total dose of 43 GyRBE in 10 fractions, 4 fractions per week. The high-dose CTV will receive a total dose of 68.8 GyRBE in 16 fractions, 4 fractions per week.~The expected duration of treatment is 4 weeks, 4 fractions per week. Treatments lasting longer than 6 weeks, or with less than 6 fractions administered on 14 consecutive days, will not be considered acceptable.~Immunotherapy: Patients will undergo immunotherapy after carbon ion radiation therapy (CIRT) up to maximum response and/or up to tolerance. The concomitant association of immunotherapy is not envisaged in this protocol.
Study: NCT02473445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cysteamine Bitartrate
Description: Cysteamine Bitartrate Delayed-release capsules
Study: NCT02558868

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study: NCT02657538

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non invasive caries treatment
Description: If the active comparator does not detect cavitation, fluoride varnish is applied on the test surface.
Study: NCT01856595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06291874
Description: The dosing schedule is 5, 15, 50, 100 and 150 mg QD for 14 days for the first 5 cohorts in Part A. The dosing schedule for the first cohort in Part B is 15 mg QD for 14 days and 30 mg QD for 28 days
Study: NCT02657538

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non invasive caries treatment
Description: If the active comparator does not detect cavitation, fluoride varnish is applied on the test surface.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Invasive caries treatment
Description: If the active comparator does detect cavitation, a composite restauration is placed

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Invasive caries treatment
Description: If the active comparator does detect cavitation, a composite restauration is placed

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Near-infrared light transillumination device (DIAGNOcam, KaVo, Biberach, Germany)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visual examination and bitewing (BW) radiography
Description: established diagnostic methods
Study: NCT01856595

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets will be administered QD in each of the cohorts for 14 days (Part A cohorts 1- 5 and Part B cohort 1) or 28 days (Part B cohort 2).
Study: NCT01081873

Intervention type: DRUG
Intervention: leuprolide (Lucrin/Lucrin-Tri-depot)
Description: Subcutaneous or intramuscular administration for all participants
Study: NCT00697047

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated Mailing
Description: Usual Care plus Automated mailing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated Mailing Plus Assisted
Description: If not screened after automated mailing, MA assists with screening.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auto Plus Assisted Plus Navigation
Description: If not screened after automated mailing and assistance by MA, RN begins navigation.
Study: NCT03992768

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hamamatsu NanoZoomer S360MD Digital Slide Scanner System
Description: Detection of pathology features using whole slide imaging
Study: NCT03825276

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mango consumption
Description: Daily consumption of 280 g of frozen mangos during 8 weeks. The daily dose in equivalent to a 2-cups serving.
Study: NCT00187837

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SW
Description: Stepwise removal of carious tissue in 2 stages

Intervention type: PROCEDURE
Group type: OTHER
Intervention: DCE
Description: one complete excavation
Study: NCT01030536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-8015 20 mcg/kg
Description: Participants will receive 20 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
Study: NCT01483014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Study: NCT04604431

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iREACH CDS Tool
Description: Pediatric clinicians in the intervention arm will 1) receive the iREACH education module, 2) have the iREACH CDS tool integrated into the EHR templates for use at the 4-, 6-, 9-, 12-month WCC, and 3) will be reminded by EHR-embedded prompts at the 9-month WCC to ask caregivers whether peanuts were introduced and tolerated.
Study: NCT00552136

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ankle Arthroplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ankle Arthrodesis
Description: Ankle fusion surgery
Study: NCT06126159

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: multiparametric and fat-detection magnetic resonance imaging (MRI)
Description: Differentiating of renal AMLs with minimal fat and RCCs
Study: NCT03940248

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Accelerated Partial Breast Irradiation
Description: 38.5 Cobalt Gray Equivalent (CGE) given over 10 fractions
Study: NCT02494414

Intervention type: OTHER
Intervention: Long-term follow-up
Description: Vital and neurological follow-up
Study: NCT03923335

Intervention type: OTHER
Intervention: DNA methylation detection
Description: detecting the methylation status of colorectal cancer specimen

Intervention type: OTHER
Intervention: DNA methylation detection
Description: detecting the methylation status of colorectal cancer specimen
Study: NCT02149966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-348
Description: A range of doses of AG-348 will be tested based on the assessment of safety and tolerability. AG-348 will be administered by mouth (orally) each day for a period of 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered by mouth (orally) each day for a period of 14 days.